



## News Release

### **Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland for Alzheimer's Disease**

**HYDERABAD, INDIA (July' 25, 2008)** – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that the revenues for the 1<sup>st</sup> quarter are at Rs. 3229 lacs for the quarter ended Jun' 2008 compared to Rs. 2898 lacs for the corresponding previous period. PAT for the quarter stood at Rs. 160 lacs compared to Rs. 315 lacs for the corresponding previous period, a decline of 49%.

Overall for the quarter the main factor which influenced the deficit in revenues and profits is the increase in cost of inputs, less value added products and mark to market currency fluctuation effects.

Suven's major thrust on innovative R&D in Drug Discovery continues with spending of Rs. 525 lacs for the quarter (constituting 16.26% of revenue for the quarter) and a total expenditure (revenue & capital) of Rs 3015 lacs recording about 24.40% of revenue for the year.

During the Quarter Suven has commenced phase 1 clinical trial for one of its compounds for Alzheimer's disease, SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral, CNS receptor site 5-HT<sub>6</sub>, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson and Schizophrenia..

The Phase 1 study being conducted using single and multiple oral doses with the objective of assessing human safety and bioavailability of SUVN-502 in 67 healthy human beings. The single ascending dose (SAD) studies are expected to be completed by Sep 2008 and multiple ascending dose (MAD) studies are to be conducted during Oct-Dec 2008.

Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

For more information on Suven, please visit our Web site at <http://www.suven.com>

### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.***